Abstract 3185
Background
Bone targeting agents (BTA) are prescribed for the prevention of skeletal-related events in patients with bone metastases from solid tumors. The use of BTA varies by region and little is known about use in Asia. This study evaluated the utilization patterns of BTA in patients within Taiwan, Hong Kong, and Korea.
Methods
This retrospective cohort study included patients diagnosed with a solid tumor (breast, prostate, or lung cancer) and with receipt of a BTA (intravenous zoledronate, pamidronate, or denosumab). All records were retrieved from databases including: the Taiwan National Health Insurance Database (NHID) of years 2012-2017, Korea’s NHID of years 2012-2016, and Hong Kong’s Clinical Data Analysis and Reporting System (CDARS) of years 2012-2017. Descriptive analyses were conducted to describe patient characteristics, the rate of BTA use among patients with a solid tumor by year and duration of BTA use in Taiwan, Hong Kong and Korea.
Results
We identified 18,286 (54% male), 2,861 (48% male) and 12,803 (41% male) patients with a solid tumor and BTA receipt in Taiwan, Hong Kong, and Korea, respectively. The mean age at BTA recipient was 64.1 (SD 13.7) in Taiwan, 64.3 (SD 12.8) in Hong Kong, and 61.5 (SD 12.9) in Korea. For patients with BTA use, the predominant tumor type was breast cancer in Taiwan (41%) and Korea (50%), and was lung cancer (53%) in Hong Kong. For the entire study period, the rates of BTA use among solid tumor patients were 8.3% in Taiwan, 5.9% in Hong Kong and 3.1% in Korea. The rates of BTA use increased gradually during study period in each place. In year 2016, the most prevalent BTA used was denosumab (7.7%) in Taiwan and zoledronate in Hong Kong (3.7%) and Korea (1.8%). Denosumab was not available in Korea during the study period. The mean duration of BTA use was 111 (SD 154) days in Taiwan, 110 (SD 148) in Hong Kong and 133 (SD 188) days in Korea.
Conclusions
In this first analysis reporting on treatment patterns for BTA use in Asia, the results suggest variation in BTA use among places and a shorter treatment duration of BTA use in clinical practice compared with guideline recommendations. The study provided fundamental information for subsequent evaluations of how this variation in BTA use may be associated with optimal clinical outcomes in Asia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Funding
Amgen Asia Holding Limited (Hong Kong).
Disclosure
S.N. Gao: Research grant / Funding (institution): Amgen Asia Holding Limited (Hong Kong). N. Kleinman: Research grant / Funding (institution): Amgen Asia Holding Limited (Hong Kong). J. Lange: Research grant / Funding (institution): Amgen Inc., Thousand Oaks, CA, USA. T.C. Lin: Research grant / Funding (institution): Amgen Inc., Thousand Oaks, CA, USA. All other authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract